Levodopa in the treatment of Parkinson's disease: Current status and new developments

Journal of Parkinson's Disease

Volumn 3, Issue 3, 2013, Pages 255-269

  Salat, David ^a   Tolosa, Eduardo ^b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Dyskinesia; Entacapone; Levodopa carbidopa; Parkinson's disease; Wearing off

Indexed keywords

CARBIDOPA PLUS ENTACAPONE PLUS LEVODOPA; CARBIDOPA PLUS LEVODOPA; DOPA DECARBOXYLASE INHIBITOR; ENTACAPONE; LEVODOPA; PLACEBO;

AKATHISIA; ANXIETY; CONFUSION; DEPRESSION; DISEASE ASSOCIATION; DISEASE COURSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; EARLY INTERVENTION; FATIGUE; HALLUCINATION; HUMAN; HYPOTENSION; IRRITABILITY; MOOD CHANGE; MOTOR DYSFUNCTION; NAUSEA; NONHUMAN; ORTHOSTATIC HYPERTENSION; PAIN; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SOMNOLENCE; SWEATING; THINKING IMPAIRMENT; TREATMENT OUTCOME; TREATMENT PLANNING; VOMITING;

ANTIPARKINSON AGENTS; DYSKINESIA, DRUG-INDUCED; HUMANS; LEVODOPA; PARKINSON DISEASE;

EID: 84888874688     PISSN: 18777171     EISSN: 1877718X     Source Type: Journal    
DOI: 10.3233/JPD-130186     Document Type: Review

References (127)

1. Pirker W (2003) Correlation of dopamine transporter imaging with parkinsonian motor handicap: How close is it? Mov Disord, 18(Suppl 7), S43-S51
2. Fearnley JM, & Lees AJ (1991) Ageing and Parkinson's disease: Substantia nigra regional selectivity Brain, 114, 2283-2301
3. Damier P, Hirsch EC, Agid Y, & Graybiel AM (1999) The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain, 122 (Pt 8), 1437-1448
4. Tolosa E, Gaig C, Santamaria J,&Compta Y (2009) Diagnosis and the premotor phase of Parkinson disease. Neurology, 72, S12-S20
5. Hughes AJ, Daniel SE, Kilford L, & Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson's disease: A clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry, 55, 181-184
6. Poewe W (2009) Clinical measures of progression in Parkinson's disease. Mov Disord, 24(Suppl 2), S671-S676
7. Fahn S (2005) Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252, iv37-iv42
8. Sethi KD (2010) The impact of levodopa on quality of life in patients with Parkinson disease Neurologist, 16, 76-83
9. Grandas F, Martinez-Martin P,&Linazasoro G (1998) Quality of life in patients with Parkinson's disease who transfer from standard levodopa to Sinemet CR: The STAR Study. The STAR Multicenter Study Group. J Neurol, 245(Suppl 1), S31-S33
10. Cotzias GC (1969) Parkinsoism and Dopa. J Chronic Dis, 22, 297-301
11. Agid Y, Olanow CW, & Mizuno Y (2002) Levodopa: Why the controversy? Lancet, 360, 575
12. Papavasiliou PS, Cotzias GC, Duby SE, Steck AJ, Fehling C, & Bell MA (1972) Levodopa in Parkinsonism: Potentiation of central effects with a peripheral inhibitor N Engl J Med, 286, 8-14
13. Birkmayer W, & Mentasti M (1967) [Further experimental studies on the catecholamine metabolism in extrapyramidal diseases (Parkinson and chorea syndromes)]. Arch Psychiatr Nervenkr, 210, 29-35
14. Huebert ND, Palfreyman MG, & Haegele KD (1983) A comparison of the effects of reversible and irreversible inhibitors of aromatic L-Amino acid decarboxylase on the half-life and other pharmacokinetic parameters of oral L-3,4-dihydroxyphenylalanine. Drug Metab Dispos, 11, 195-200
15. Cedarbaum JM, Kutt H, & McDowell FH (1989) A pharmacokinetic and pharmacodynamic comparison of Sinemet CR (50/200) and standard Sinemet (25/100). Neurology, 39, 38-44; discussion 59
16. MacMahon DG, Sachdev D, Boddie HG, Ellis CJ, Kendal BR, & Blackburn NA (1990) A comparison of the effects of controlled-release levodopa (Madopar CR) with conventional levodopa in late Parkinson's disease. J Neurol Neurosurg Psychiatry, 53, 220-223
17. Sage JI, & Mark MH (1994) Pharmacokinetics of continuous-release carbidopa/levodopa. Clin Neuropharmacol, 17(Suppl 2), S1-S6
18. Benetello P, Furlanut M, Fortunato M, Pea F, & Baraldo M (1997) Levodopa and 3-O-methyldopa in cerebrospinal fluid after levodopa-carbidopa association. Pharmacol Res, 35, 313-315
19. Gauthier S,&Amyot D (1992) Sustained release antiparkinson agents: Controlled release levodopa. Can J Neurol Sci, 19, 153-155
20. Wolters EC, & Tesselaar HJM (1996) International (NKUK) double-blind study of sinemetCRand standard sinemet (25/100) in 170 patients with fluctuating Parkinson's disease. Journal of Neurology, 243, 235-240
21. Block G, Liss C, Reines S, Irr J, & Nibbelink D (1997) Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group. Eur Neurol, 37, 23-27
22. Jankovic J, Schwartz K, & Vander Linden C (1989) Comparison of Sinemet CR4 and standard Sinemet: Double blind and long-Term open trial in parkinsonian patients with fluctuations. Mov Disord, 4, 303-309
23. Goetz CG, Tanner CM, Shannon KM, Carroll VS, Klawans HL, Carvey PM, & Gilley D (1988) Controlled-release carbidopa/levodopa (CR4-Sinemet) in Parkinson's disease patients with and without motor fluctuations. Neurology, 38, 1143-1146
24. Koller WC, Hutton JT, Tolosa E, & Capilldeo R (1999) Immediate-release and controlled-release carbidopa/ levodopa in PD: A 5-year randomized multicenter study. Carbidopa/Levodopa Study Group. Neurology, 53, 1012-1019
25. Kaakkola S, Teravainen H, Ahtila S, Rita H, & Gordin A (1994) Effect of entacapone, a COMT inhibitor, on clinical disability and levodopa metabolism in parkinsonian patients. Neurology, 44, 77-80
26. Gordin A, Kaakkola S, & Teravainen H (2004) Clinical advantages of COMT inhibition with entacapone-A review. J Neural Transm, 111, 1343-1363
27. Parkinson Study Group (1997) Entacapone improves motor fluctuations in levodopa-Treated Parkinson's disease patients. Ann Neurol, 42, 747-755
28. Rinne UK, Larsen JP, Siden A, & Worm-Petersen J (1998) Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. NOMECOMT Study Group. Neurology, 51, 1309-1314
29. Poewe WH, Deuschl G, Gordin A, Kultalahti ER, & Leinonen M (2002) Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: A 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). Acta Neurol Scand, 105, 245-255
30. Brooks DJ, & Sagar H (2003) Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: A randomised, placebo controlled, double blind, six month study. J Neurol Neurosurg Psychiatry, 74, 1071-1079
31. Stocchi F, Rascol O, Kieburtz K, Poewe W, Jankovic J, Tolosa E, Barone P, Lang AE, & Olanow CW (2010) Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: The STRIDE-PD study. Ann Neurol, 68, 18-27
32. Stowe R, Ives N, Clarke CE, HandleyK, Furmston A, Deane K, van Hilten JJ, WheatleyK&Gray R (2011) Meta-Analysis of the comparative efficacy and safety of adjuvant treatment to levodopa in later Parkinson's disease. Mov Disord, 26, 587-598
33. Antonini A, Abbruzzese G, Barone P, Bonuccelli U, Lopiano L, Onofrj M, Zappia M, & Quattrone A (2008) COMT inhibition with tolcapone in the treatment algorithm of patients with Parkinson's disease (PD): Relevance for motor and non-motor features. Neuropsychiatr Dis Treat, 4, 1-9
34. Kiss LE, Ferreira HS, Torrao L, Bonifacio MJ, Palma PN, Soares-da-Silva P, & Learmonth DA (2010) Discovery of a long-Acting, peripherally selective inhibitor of catechol-Omethyltransferase. J Med Chem, 53, 3396-3411
35. Tolosa ES, Martin WE, Cohen HP, & Jacobson RL (1975) Patterns of clinical response and plasma dopa levels in Parkinson's disease. Neurology, 25, 177-183
36. Muenter MD,&TyceG M (1971) L-dopa therapy of Parkinson's disease: Plasma L-dopa concentration, therapeutic response, and side effects. Mayo Clin Proc, 46, 231-239
37. Melamed E (1979) Early-morning dystonia. A late side effect of long-Term levodopa therapy in Parkinson's disease. Arch Neurol, 36, 308-310
38. Poewe WH, Lees AJ, & Stern GM (1988) Dystonia in Parkinson's disease: Clinical and pharmacological features. Ann Neurol, 23, 73-78
39. Witjas T, Kaphan E, Azulay JP, Blin O, Ceccaldi M, Pouget J, Poncet M, & Cherif AA (2002) Nonmotor fluctuations in Parkinson's disease: Frequent and disabling. Neurology, 59, 408-413
40. Stacy M, Bowron A, Guttman M, Hauser R, Hughes K, Larsen JP, Lewitt P, OertelW, Quinn N, Sethi K,&Stocchi F (2005) Identification of motor and nonmotor wearing-off in Parkinson's disease: Comparison of a patient questionnaire versus a clinician assessment. Mov Disord, 20, 726-733
41. de la Fuente-Fernandez R, Lu JQ, Sossi V, Jivan S, Schulzer M, Holden JE, Lee CS, Ruth TJ, Calne DB, & Stoessl AJ (2001) Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover. Ann Neurol, 49, 298-303
42. de la Fuente-Fernandez R, Sossi V, Huang Z, Furtado S, Lu JQ, Calne DB, Ruth TJ, & Stoessl AJ (2004) Levodopainduced changes in synaptic dopamine levels increase with progression of Parkinson's disease: Implications for dyskinesias. Brain, 127, 2747-2754
43. Chase TN (1998) The significance of continuous dopaminergic stimulation in the treatment of parkinson's disease. Drugs, 55, 1-9
44. Obeso JA, Rodriguez-Oroz MC, Rodriguez M, DeLong MR, & Olanow CW (2000) Pathophysiology of levodopainduced dyskinesias in Parkinson's disease: Problems with the current model. Ann Neurol, 47, S22-32; discussion S32-24
45. Cenci MA (2007) Dopamine dysregulation of movement control in L-DOPA-induced dyskinesia. Trends Neurosci, 30, 236-243
46. Stocchi F (2010) The concept of continuous dopaminergic stimulation: What we should consider when starting Parkinson's disease treatment. Neurodegener Dis, 7, 213-215
47. Fahn S, Oakes D, Shoulson I, Kierburtz K, Rudolph A, Lang A, Olanow W, & Marek K (2004) Levodopa and the progression of Parkinson's disease. N Engl J Med, 351, 2498-2508
48. Kumar N, Van Gerpen JA, Bower JH, & Ahlskog JE (2005) Levodopa-dyskinesia incidence by age of Parkinson's disease onset. Mov Disord, 20, 342-344
49. Quinn N, Critchley P, & Marsden CD (1987) Young onset Parkinson's disease. Mov Disord, 2, 73-91
50. Ahlskog JE,&MuenterM D (2001) Frequency of levodoparelated dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord, 16, 448-458
51. Castro-Garcia A (1997) [Psychiatric complications of L-dopa: Physiopathology and treatment]. Rev Neurol, 25(Suppl 2), S157-S162
52. Vilas D, Pont-Sunyer C, & Tolosa E (2012) Impulse control disorders in Parkinson's disease. Parkinsonism Relat Disord, 18(Suppl 1), S80-84
53. Weintraub D, Koester J, Potenza MN, Siderowf AD, Stacy M, Voon V, Whetteckey J, Wunderlich GR, & Lang AE (2010) Impulse control disorders in Parkinson disease: A cross-sectional study of 3090 patients. Arch Neurol, 67, 589-595
54. Molina JA, Sainz-ArtigaMJ, Fraile A, Jimenez-Jimenez FJ, Villanueva C, Orti-ParejaM,&Bermejo F (2000) Pathologic gambling in Parkinson's disease: A behavioral manifestation of pharmacologic treatment? Mov Disord, 15, 869-872
55. van Deelen RA, Rommers MK, Eerenberg JG & Egberts AC (2002) [Hypersexuality during use of levodopa] Ned Tijdschr Geneeskd, 146, 2095-2098
56. O'Sullivan SS, Evans AH, & Lees AJ (2009) Dopamine dysregulation syndrome: An overview of its epidemiology, mechanisms and management. CNS Drugs, 23, 157-170
57. Evans AH, Pavese N, Lawrence AD, TaiYF, Appel S, Doder M, Brooks DJ, Lees AJ,&Piccini P (2006) Compulsive drug use linked to sensitized ventral striatal dopamine transmission. Ann Neurol, 59, 852-858
58. Pezzella FR, Colosimo C, Vanacore N, Di Rezze S, Chianese M, Fabbrini G, & Meco G (2005) Prevalence and clinical features of hedonistic homeostatic dysregulation in Parkinson's disease. Mov Disord, 20, 77-81
59. Evans AH, Lawrence AD, Potts J, Appel S, & Lees AJ (2005) Factors influencing susceptibility to compulsive dopaminergic drug use in Parkinson disease. Neurology, 65, 1570-1574
60. Spencer AH, Rickards H, Fasano A, & Cavanna AE (2011) The prevalence and clinical characteristics of punding in Parkinson's disease. Mov Disord, 26, 578-586
61. Fasano A, Ricciardi L, Pettorruso M, & Bentivoglio AR (2011) Management of punding in Parkinson's disease: An open-label prospective study. J Neurol, 258, 656-660
62. Broen M, Duits A, Visser-Vandewalle V, Temel Y, & Winogrodzka A (2011) Impulse control and related disorders in Parkinson's disease patients treated with bilateral subthalamic nucleus stimulation: A review. Parkinsonism Relat Disord, 17, 413-417
63. Oertel WH, Berardelli A, Bloem BR, Bonuccelli U, Burn D, Deuschl G, Dietrichs E, Fabbrini G, Ferreira JJ, Friedman A, Kanovsky P,KosticV, Nieuwboer A, Odin P, PoeweW, Rascol O, Sampaio C, Schüpbach M, Tolosa E, & Trenkwalder C (2010) Chapter 15: Late (complicated) Parkinson's disease. In: Nils Erik Gilhus, Michael R. Barnes, Brainin M, editors, European Handbook of Neurological Management, Wiley-Blackwell, p. 584
64. Au WL, Adams JR, Troiano AR, & Stoessl AJ (2005) Parkinson's disease: In vivo assessment of disease progression using positron emission tomography. Brain Res Mol Brain Res, 134, 24-33
65. Fox SH, Katzenschlager R, Lim SY, Ravina B, Seppi K, Coelho M, Poewe W, Rascol O, Goetz CG, & Sampaio C (2011) The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease. Mov Disord, 26(Suppl 3), S2-S41
66. Seppi K, Weintraub D, Coelho M, Perez-Lloret S, Fox SH, Katzenschlager R, Hametner EM, PoeweW, Rascol O, Goetz CG, & Sampaio C (2011) The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease. Mov Disord, 26(Suppl 3), S42-S80
67. The National Collaborating Centre for Chronic Conditions. Parkinson's disease: National clinical guideline for diagnosis and management in primary and secondary care. Royal College of Physicians, London, 2006
68. Hauser RA, Rascol O, Korczyn AD, Jon Stoessl A, Watts RL, Poewe W, De Deyn PP, & Lang AE (2007) Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. Mov Disord, 22, 2409-2417
69. Lees AJ, Katzenschlager R, Head J,&Ben-Shlomo Y (2001) Ten-year follow-up of three different initial treatments in de-novo PD: A randomized trial. Neurology, 57, 1687-1694
70. Jankovic J (2001) Parkinson's disease therapy: Treatment of early and late disease. Chin Med J (Engl), 114, 227-234
71. Antonini A, Tolosa E, Mizuno Y, Yamamoto M, & Poewe WH (2009)Areassessment of risks and benefits of dopamine agonists in Parkinson's disease. Lancet Neurol, 8, 929-937
72. Hauser RA, Panisset M, Abbruzzese G, Mancione L, Dronamraju N, & Kakarieka A (2009) Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease. Mov Disord, 24, 541-550
73. Barone P, Poewe W, Albrecht S, Debieuvre C, Massey D, Rascol O, Tolosa E, & Weintraub D (2010) Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: A randomised, double-blind, placebocontrolled trial. Lancet Neurol, 9, 573-580
74. Stocchi F, Barbato L, Nordera G, Berardelli A, & Ruggieri S (1998) Sleep disorders in Parkinson's disease. J Neurol, 245(Suppl 1), S15-S18
75. Tan A, Salgado M, & Fahn S (1996) Rapid eye movement sleep behavior disorder preceding Parkinson's disease with therapeutic response to levodopa. Mov Disord, 11, 214-216
76. Iranzo A, Molinuevo JL, Santamaria J, Serradell M, Marti MJ,Valldeoriola F,&Tolosa E (2006) Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: A descriptive study. Lancet Neurol, 5, 572-577
77. Schestatsky P, Kumru H, Valls-Sole J, Valldeoriola F, Marti MJ, Tolosa E,&ChavesML (2007) Neurophysiologic study of central pain in patients with Parkinson disease. Neurology, 69, 2162-2169
78. Schifitto G, Friedman JH, Oakes D, Shulman L, Comella CL, Marek K, Fahn S, & Parkinson Study Group EI (2008) Fatigue in levodopa-naive subjects with Parkinson disease. Neurology, 71, 481-485
79. Fetoni V, Soliveri P, Monza D, Testa D & Girotti F (1999) Affective symptoms in multiple system atrophy and Parkinson's disease: Response to levodopa therapy. J Neurol Neurosurg Psychiatry, 66, 541-544
80. Eskow Jaunarajs KL, Angoa-Perez M, Kuhn DM, & Bishop C (2011) Potential mechanisms underlying anxiety and depression in Parkinson's disease: Consequences of l-DOPA treatment. Neurosci Biobehav Rev, 35, 556-564
81. Molloy SA, Rowan EN, O'Brien JT, McKeith IG, Wesnes K, & Burn DJ (2006) Effect of levodopa on cognitive function in Parkinson's disease with and without dementia and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry, 77, 1323-1328
82. Lange KW, Robbins TW, Marsden CD, James M, Owen AM & Paul GM (1992) L-dopa withdrawal in Parkinson's disease selectively impairs cognitive performance in tests sensitive to frontal lobe dysfunction. Psychopharmacology (Berl), 107, 394-404
83. Gotham AM, Brown RG & Marsden CD (1988) 'Frontal' cognitive function in patients with Parkinson's disease 'on' and 'off' levodopa. Brain, 111(Pt 2), 299-321
84. Pascual-Sedano B, Kulisevsky J, Barbanoj M, Garcia-Sanchez C, Campolongo A, Gironell A, Pagonabarraga J, & Gich I (2008) Levodopa and executive performance in Parkinson's disease: A randomized study. J Int Neuropsychol Soc, 14, 832-841
85. GershanikO S (2010) Clinical problems in late-stage Parkinson's disease. J Neurol, 257, S288-S291
86. Harder S,&Baas H (1998) Concentration-response relationship of levodopa in patients at different stages of Parkinson's disease. Clin Pharmacol Ther, 64, 183-191
87. Politis M, Wu K, Molloy S, P GB, Chaudhuri KR, & Piccini P (2010) Parkinson's disease symptoms: The patient's perspective. Mov Disord, 25, 1646-1651
88. Hattori N, Fujimoto K, Kondo T, Murata M, & Stacy M (2010) Patient perspectives towards levoodpa therapy in Japan and the United States-results of two patient surveys. Mov Disord, 25, S569-S717
89. Stocchi F (2006) The levodopa wearing-off phenomenon in Parkinson's disease: Pharmacokinetic considerations. Expert Opin Pharmacother, 7, 1399-1407
90. Wullner U, Fuchs G, Reketat N, Randerath O,&Kassubek J (2012) Requirements for Parkinson's disease pharmacotherapy from the patients' perspective: A questionnaire-based survey. Curr Med Res Opin, 28, 1239-1246
91. Pahwa R, Lyons K, McGuire D, Dubinsky R, Hubble JP, & Koller WC (1996) Early morning akinesia in Parkinson's disease: Effect of standard carbidopa/levodopa and sustained-release carbidopa/levodopa. Neurology, 46, 1059-1062
92. Grosset KA, Reid JL,&GrossetD G (2005) Medicine-Taking behavior: Implications of suboptimal compliance in Parkinson's disease. Mov Disord, 20, 1397-1404
93. Koller WC, & Pahwa R (1994) Treating motor fluctuations with controlled-release levodopa preparations. Neurology, 44, S23-28
94. Muller T, Erdmann C, Muhlack S, Bremen D, Przuntek H, Goetze O, &Woitalla D (2006) Pharmacokinetic behaviour of levodopa and 3-O-methyldopa after repeat administration of levodopa/carbidopa with and without entacapone in patients with Parkinson's disease J Neural Transm, 113, 1441-1448
95. Brooks DJ, Agid Y, Ostergaard JR, Widner H, & Oertel W (2003) A new triple combination tablet is easy to initiate and provides symptom control in patients with Parkinson's disease. Eur J Neurol, 10(Suppl 1), 241 (Abstract
96. Ingman K, Naukkarinen T, Vahteristo M, Korpela I, Kuoppamaki M, & Ellmen J (2012) The effect of different dosing regimens of levodopa/carbidopa/ entacapone on plasma levodopa concentrations. Eur J Clin Pharmacol, 68, 281-289
97. Kuoppamäki M, Sauramo A, Korpela K, Vahteristo M, Kailajärvi M, Lehtinen T, & Ellm'en J (2010) Night-Time bioavailability of levodopa/carbidopa/entacapone is higher compared with controlled-release levodopa/carbidopa. Int J Clin Pharmacol and Ther 48, 756-760
98. Sauramo A, Korpela K, Vahteristo M, Kuoppamaki M, Kailiajarvi M, Lehtinen T, Ellmen J, & Nissinen H (2008) Pharmacokinetic profile of levodopa after a single night-Time dose or after repeated daily dosing of levodopa/carbidopa/ entacapone 200/50/200mg (Stalevo®) compared with controlled-release levodopa/carbidopa 200/50mg (Sinemet® CR) in healthy volunteers. Ann Neurol, 64, S1-S139 (Abstract T-171
99. Verhagen Metman L, Del Dotto P, van den Munckhof P, Fang J, MouradianMM,&ChaseT N (1998) Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology, 50, 1323-1326
100. Snow BJ, Macdonald L, McAuley D, & Wallis W (2000) The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: A double-blind, placebo-controlled study. Clin Neuropharmacol, 23, 82-85
101. Durif F, Debilly B, Galitzky M, Morand D, Viallet F, Borg M, Thobois S, Broussolle E, & Rascol O (2004) Clozapine improves dyskinesias in Parkinson disease: A double-blind, placebo-controlled study. Neurology, 62, 381-388
102. Katzenschlager R, Manson AJ, Evans A, Watt H, & Lees AJ (2004) Low dose quetiapine for drug induced dyskinesias in Parkinson's disease: A double blind cross over study. J Neurol Neurosurg Psychiatry, 75, 295-297
103. Cenci MA, Ohlin KE, & Odin P (2011) Current options and future possibilities for the treatment of dyskinesia and motor fluctuations in Parkinson's disease. CNS Neurol Disord Drug Targets, 10, 670-684
104. Quinn N, & Marsden CD (1986) Lithium for painful dystonia in Parkinson's disease. Lancet, 1, 1377
105. Pacchetti C, Albani G, Martignoni E, Godi L, Alfonsi E, & Nappi G (1995) "Off" painful dystonia in Parkinson's disease treated with botulinum toxin. Mov Disord, 10, 333-336
106. Bredberg E, Nilsson D, Johansson K, Aquilonius SM, Johnels B, Nyström C, & Paalzow L (1993) Intraduodenal infusion of a water-based levodopa dispersion for optimisation of the therapeutic effect in severe Parkinson's disease. Eur J Clin Pharmacol, 45, 117-122
107. Syed N, Murphy J, Zimmerman T, Jr., Mark MH, & Sage JI (1998) Ten years' experience with enteral levodopa infusions for motor fluctuations in Parkinson's disease. Mov Disord, 13, 336-338
108. Nilsson D, Nyholm D, & Aquilonius SM (2001) Duodenal levodopa infusion in Parkinson's disease-long-Term experience. Acta Neurol Scand, 104, 343-348
109. Antonini A, Isaias IU, Canesi M, Zibetti M, Mancini F, Manfredi L, Dal Fante M, Lopiano L, & Pezzoli G (2007) Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome. Mov Disord, 22, 1145-1149
110. Devos D on behalf of the French DUODOPA Study Group (2009) Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease. Mov Disord, 24, 993-1000
111. Puente V, De Fabregues O, Oliveras C, Ribera G, Pont-Sunyer C, Vivanco R, Cucurella G, Giralt E, Delgado T, Garcia C, Seoane A, & Campo R (2010) Eighteen month study of continuous intraduodenal levodopa infusion in patients with advanced Parkinson's disease: Impact on control of fluctuations and quality of life. Parkinsonism Relat Disord, 16, 218-221
112. Fasano A, Ricciardi L, Lena F, Bentivoglio AR, & Modugno N (2012) Intrajejunal levodopa infusion in advanced Parkinson's disease: Long-Term effects on motor and nonmotor symptoms and impact on patient's and caregiver's quality of life. Eur Rev Med Pharmacol Sci, 16, 79-89
113. Nyholm D (2012) Duodopa(R) treatment for advanced Parkinson's disease:Areviewof efficacy and safety. Parkinsonism Relat Disord, 18, 916-929
114. Nyholm D, Lewander T, Johansson A, Lewitt PA, Lundqvist C, & Aquilonius SM (2008) Enteral levodopa/carbidopa infusion in advanced Parkinson disease: Long-Term exposure. Clin Neuropharmacol, 31, 63-73
115. Honig H, Antonini A, Martinez-Martin P, Forgacs I, Faye GC, Fox T, Fox K, Mancini F, Canesi M, Odin P, & ChaudhuriKR(2009) Intrajejunal levodopa infusion in Parkinson's disease: A pilot multicenter study of effects on nonmotor symptoms and quality of life. Mov Disord, 24, 1468-1474
116. Fernandez HH, Vanagunas A, Odin P, Espay AJ, Hauser RA, Standaert DG, Chatamra K, Benesh J, Pritchett Y, Hass SL, & Lenz RA (2013) Levodopa-carbidopa intestinal gel in advanced Parkinson's disease open-label study: Interim results. Parkinsonism Relat Disord, 19, 339-345
117. Olanow CW, Antonini A, Kieburtz K, Fernandez HH, Espay AJ, Standaert DG, & Vanagunas AD (2012) Randomized, double-blind, double-dummy study of continuous infusion of levodopa-carbidopa intestinal gel in patients with advanced Parkinson's disease: Efficacy and safety [abstract]. Mov Disord, 27(Suppl 1), 411
118. Kieburtz K, Antonini A, OlanowCW, Fernandez HH, Espay AJ, Standaert DG, & Hass S (2012) Randomized, phase 3, double-blind, double-dummy study of levodopa-carbidopa intestinal gel in patients with advanced Parkinson's disease: Functional and quality-of-life outcomes [abstract].Mov Disord, 27(Suppl 1), 385
119. Urban PP, Wellach I, Faiss S, Layer P, Rosenkranz T, Knop K, & Weis J (2010) Subacute axonal neuropathy in Parkinson's disease with cobalamin and vitamin B6 deficiency under duodopa therapy. Mov Disord, 25, 1748-1752
120. MullerT, Jugel C, Ehret R, Ebersbach G, Bengel G, Muhlack S, & Klostermann F (2011) Elevation of total homocysteine levels in patients with Parkinson's disease treated with duodenal levodopa/carbidopa gel. J Neural Transm, 118, 1329-1333
121. Müller T, Laar Tv, Cornblath DR, Odin P, Klostermann F, Grandas FJ, Ebersbach G, Urban PP, Valldeoriola F, & Antonini A (2013) Peripheral neuropathy in Parkinson's disease: Levodopa exposure and implications for duodenal delivery. Parkinsonism Relat Disord, 19, 501-507
122. Hauser RA, Ellenbogen AL, Metman LV, Hsu A, O'Connell MJ, Modi NB, Yao HM, Kell SH, & Gupta SK (2011) Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's disease. Mov Disord, 26, 2246-2252
123. Hauser RA (2011) Future treatments for Parkinson's disease: Surfing the PD pipeline. Int J Neurosci, 121(Suppl 2), 53-62
124. Di Stefano A, Sozio P, Cerasa LS, & Iannitelli A (2011) L-Dopa prodrugs: An overview of trends for improving Parkinson's disease treatment. Curr Pharm Des, 17, 3482-3493
125. Sudo J, Iwase H, Higashiyama K, Kakuno K, Miyasaka F, Meguro T, & Takayama K (2002) Elevation of plasma levels of L-dopa in transdermal administration of L-dopabutylester in rats. Drug Dev Ind Pharm, 28, 59-65
126. Ondo WG, Shinawi L, & Moore S (2010) Comparison of orally dissolving carbidopa/levodopa (Parcopa) to conventional oral carbidopa/levodopa:Asingle- dose, double-blind, double-dummy, placebo-controlled, crossover trial. Mov Disord, 25, 2724-2727
127. Stocchi F, Zappia M, Dall'Armi V, Kulisevsky J, Lamberti P, Obeso JA,&Melevodopa Plus Carbidopa Study G (2010) Melevodopa/carbidopa effervescent formulation in the treatment of motor fluctuations in advanced Parkinson's disease. Mov Disord, 25, 1881-1887